Investigating the role of APOC3 in heart and kidney diseases related to diabetes
Official title: APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis
Funded at University of Washington · NIH-10774240 · Data updated 2026-11-12
This study is looking at how a protein called APOC3 affects heart and kidney problems in people with diabetes, and it hopes to find out if blocking this protein can help prevent kidney disease, especially in those with both diabetes and kidney issues, which might raise the risk of heart disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | February 17, 2020 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $372,768 |
| NIH project number | 5R01DK121756-05 |
| Project ID | NIH-10774240 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults with diabetes who are at risk for cardiovascular and kidney diseases.
✕Less likely to help
Patients without diabetes or those who do not have any cardiovascular or kidney complications may not benefit from this research.
What this research studies
This research focuses on understanding how apolipoprotein C3 (APOC3) contributes to heart and kidney diseases in people with diabetes. It aims to determine if blocking APOC3 can prevent diabetic kidney disease and if diabetes combined with kidney impairment increases APOC3 levels, leading to a higher risk of atherosclerosis. The study will utilize mouse models to test these hypotheses through specific targeting of APOC3 using innovative techniques. Patients may benefit from insights that could lead to new treatments for managing their conditions.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing heart and kidney complications in diabetic patients.
How similar studies have gone: Previous research has shown promising results in targeting APOC3 for cardiovascular conditions, suggesting potential success for this approach.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Kanter, Jenny E. — University of Washington
- Study coordinator: Kanter, Jenny E.
Related research
Other NIH-funded projects on the same topics.
-
siRNA nanoparticle treatment to stop diabetic kidney damage
A new nanoparticle-delivered gene-silencing treatment aims to lower kidney inflammation in people with diabetes to help protect their kidneys.
-
LRG1’s role in diabetic kidney disease and kidney fibrosis
A study examines how a specific protein, LRG1, influences kidney disease related to diabetes and its scarring, with the aim of finding targeted ways to slow or prevent damage.
-
Potential Effects of a Plasticizer on Dyslipidemia and Atherosclerosis
A study in young models looks at how certain plastic chemicals might influence cholesterol and artery disease through a key liver receptor.
-
Fabkin, a New Hormone Complex, and Its Role in Lipids and Inflammation Driving Atherosclerosis
A new hormone complex called Fabkin is being studied to see if it links fat metabolism and inflammation in atherosclerosis so future treatments could target both problems.
-
Genetic discovery for diabetic kidney disease in adults
A scientist team is studying the genes that influence diabetic kidney disease in adults to better understand why some people develop it.
-
Non-canonical NF-kB and inflammation in diabetic kidney disease
A study to understand how a specific inflammatory pathway worsens kidney disease in adults with type 2 diabetes and how it might be treated.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.